Artelo Biosciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$12.7MTTM through 30 Jun 2026
Free Cash Flow -$12.6MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-253.6%ROE
Balance Sheet Health
Debt / Equity-0.53x
Current Ratio0.17x
Net Debt$78K
Cash & Equivalents$4.2M
Quality Metrics
Altman Z-Score-19.01
Piotroski F-Score2 / 9
Earnings-Beat Rate33.3%
Multi-Year Trend
Diluted EPS-$11.42TTMFY2025: $-12.52
Dividend
No dividend
Capital Allocation
R&D Spend$3.8M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.